Why the study?
Reports emerged of myocarditis and pericarditis predominantly in young males after the second dose of mRNA COVID-19 vaccines, prompting a review of benefits and risks.
Do the benefits of mRNA COVID-19 vaccines outweigh the risks of myocarditis in persons aged ≥12 years?
Population
Persons aged ≥12 years recommended for COVID-19 vaccination in the United States
Design
Advisory committee evidence review and updated recommendations
Authors
Loading...
Supports continued mRNA COVID-19 vaccination for all persons aged ≥12 years; reinforces ACIP guidance with updated risk-benefit data.
Do the benefits of mRNA COVID-19 vaccines outweigh the risks of myocarditis in persons aged ≥12 years?
The ACIP recommends continued use of mRNA COVID-19 vaccines in all eligible populations, concluding that the benefits of vaccination clearly outweigh the rare risk of myocarditis.
Gargano et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: